Mixed-type dry eye—the most prevalent clinical form of the condition—involves concurrent abnormalities across multiple tear film components, including aqueous deficiency, meibomian gland dysfunction (leading to lipid layer instability), and chronic ocular surface inflammation. This multifactorial pathophysiology results in more complex, refractory symptoms that often respond poorly to monotherapy with conventional artificial tears—whether water-based or lipid-enhancing formulations.
At the core of mixed-type dry eye lies a self-perpetuating inflammatory cascade. Emerging evidence underscores that inflammation is not merely a secondary consequence but a primary driver that amplifies tear film instability, goblet cell loss, and epithelial damage. Consequently, targeted anti-inflammatory therapy has become a cornerstone of modern management—not just for symptom relief, but to modify disease progression.
Low-concentration cyclosporine ophthalmic emulsion (0.05%) is now widely recognized as a first-line pharmacologic intervention for moderate-to-severe mixed-type dry eye. As outlined in the *2026 Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach*, this formulation is recommended as initial disease-modifying therapy. Similarly, the *2024 Chinese Expert Consensus on Clinical Diagnosis and Management of Dry Eye* affirms its role in selectively inhibiting T-lymphocyte activation and downstream pro-inflammatory cytokine release—including IL-2, TNF-α, and IFN-γ—thereby restoring homeostasis to the ocular surface.
Unlike symptomatic lubricants, 0.05% cyclosporine exerts dual therapeutic effects: it dampens chronic inflammation while concurrently stimulating both aqueous tear production and mucin secretion by conjunctival goblet cells. This dual action directly addresses two fundamental deficits in mixed-type disease—tear volume insufficiency and mucin layer disruption—making it uniquely suited to the heterogeneous pathology.
A key clinical advantage lies in its ability to interrupt the vicious cycle of dry eye progression: tear film instability triggers inflammation, which further degrades tear quality and quantity, thereby worsening instability. By suppressing this inflammatory feedback loop, cyclosporine helps prevent escalation from mild to moderate or severe disease—a critical consideration given that untreated mixed-type dry eye frequently progresses to corneal epitheliopathy and visual disturbance.
From a practical standpoint, this cyclosporine formulation (specifically the preservative-free version marketed as Zirun Cyclosporine Ophthalmic Emulsion II) demonstrates excellent compatibility within multimodal treatment regimens. Its lack of preservatives minimizes risk of preservative-induced toxicity and allows safe co-administration—when appropriately spaced—with various artificial tears (including hyaluronic acid–based, lipid-containing, and osmoprotective formulations), as well as corneal repair agents such as rebamipide or diquafosol. This flexibility supports integration into comprehensive care plans that may also include lid hygiene, thermal pulsation therapy, or intense pulsed light.
While cyclosporine serves as the central anti-inflammatory anchor in mixed-type dry eye management, optimal outcomes require individualized, layered strategies. Patients with predominant meibomian gland dysfunction benefit from daily warm compresses and eyelid massage; those with aqueous deficiency may require environmental modifications—such as humidification and reduced screen time—to minimize evaporative loss. Avoiding mechanical trauma (e.g., eye rubbing), ensuring adequate sleep, and scheduling regular ophthalmologic reassessments remain essential adjuncts to pharmacotherapy.
Clinicians emphasize that cyclosporine monotherapy is rarely sufficient for moderate-to-severe cases. Most patients require combination therapy—cyclosporine plus lubricating drops, physical interventions, and lifestyle adjustments—tailored through objective assessment (e.g., tear breakup time, meibography, corneal staining, and inflammatory biomarkers where available). Symptom improvement typically begins within four weeks, with maximal stabilization observed after approximately three months of consistent, twice-daily dosing.